Anxiety Disorders - Pipeline Review, H2 2016

  • ID: 3895081
  • Report
  • 273 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Bionomics Limited
  • Gabather AB
  • IntelGenx Corp.
  • Omeros Corporation
  • Synchroneuron Inc.
  • MORE
Anxiety Disorders - Pipeline Review, H2 2016

Summary

‘Anxiety Disorders - Pipeline Review, H2 2016’, provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Bionomics Limited
  • Gabather AB
  • IntelGenx Corp.
  • Omeros Corporation
  • Synchroneuron Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Anxiety Disorders Overview

Therapeutics Development

Pipeline Products for Anxiety Disorders - Overview

Pipeline Products for Anxiety Disorders - Comparative Analysis

Anxiety Disorders - Therapeutics under Development by Companies

Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes

Anxiety Disorders - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Anxiety Disorders - Products under Development by Companies

Anxiety Disorders - Products under Investigation by Universities/Institutes

Anxiety Disorders - Companies Involved in Therapeutics Development

AbbVie Inc

Ache Laboratorios Farmaceuticos S/A

Adamed Sp. z o.o.

Addex Therapeutics Ltd

Amorsa Therapeutics Inc.

Avineuro Pharmaceuticals, Inc.

Azevan Pharmaceuticals, Inc.

Biohaven Pharmaceutical Holding Company Limited

Bionomics Limited

Boehringer Ingelheim GmbH

C4X Discovery Holdings PLC

Catalyst Pharmaceuticals, Inc.

Corcept Therapeutics Incorporated

Edgemont Pharmaceuticals, LLC

Eisai Co., Ltd.

Eli Lilly and Company

Fabre-Kramer Pharmaceuticals, Inc.

Gabather AB

GlaxoSmithKline Plc

GW Pharmaceuticals Plc

Humanetics Corporation

IntelGenx Corp.

Intra-Cellular Therapies, Inc.

INVENT Pharmaceuticals, Inc.

Lead Discovery Center GmbH

Marinus Pharmaceuticals, Inc.

Merz Pharma GmbH & Co. KgaA

Neuralstem, Inc.

Neurelis, Inc.

NeuroNascent, Inc.

Newron Pharmaceuticals S.p.A.

Nippon Chemiphar Co., Ltd.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pherin Pharmaceuticals, Inc.

Pragma Therapeutics

Protagenic Therapeutics Inc.

Suda Ltd

Sumitomo Dainippon Pharma Co., Ltd.

Synchroneuron Inc.

Tonix Pharmaceuticals Holding Corp.

Toray Industries, Inc.

Trevena, Inc.

TRImaran Pharma, Inc.

Turing Pharmaceuticals AG

Anxiety Disorders - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

18-MC - Drug Profile

acamprosate calcium SR - Drug Profile

ACH-36 - Drug Profile

ADN-2013 - Drug Profile

ADX-71441 - Drug Profile

ADX-71743 - Drug Profile

ADX-88178 - Drug Profile

alprazolam - Drug Profile

AM-3506 - Drug Profile

AVN-0189 - Drug Profile

AVN-101 - Drug Profile

AVN-628 - Drug Profile

BNC-210 - Drug Profile

brexpiprazole - Drug Profile

CPP-115 - Drug Profile

D-473 - Drug Profile

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile

E-2508 - Drug Profile

evenamide - Drug Profile

FKW-00GA - Drug Profile

fluvoxamine maleate - Drug Profile

ganaxolone - Drug Profile

gepirone hydrochloride ER - Drug Profile

GT-001 - Drug Profile

HL-9001 - Drug Profile

HUF-101 - Drug Profile

IC-87201 - Drug Profile

INT-0036 - Drug Profile

INV-107 - Drug Profile

ITI-007 - Drug Profile

KDAC-0001 - Drug Profile

ketamine hydrochloride - Drug Profile

lorazepam - Drug Profile

lorazepam ER - Drug Profile

LSN-2535717 - Drug Profile

LY-2607540 - Drug Profile

midazolam hydrochloride - Drug Profile

modafinil - Drug Profile

nabiximols - Drug Profile

NC-2800 - Drug Profile

NEO-1940 - Drug Profile

NNI-351 - Drug Profile

NSI-189 - Drug Profile

OMS-527 - Drug Profile

Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile

PGT-117 - Drug Profile

PH-94B - Drug Profile

PN-6047 - Drug Profile

PT-00114 - Drug Profile

remeglurant - Drug Profile

riluzole - Drug Profile

Rycal - Drug Profile

S-107 - Drug Profile

SCT-66 - Drug Profile

Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile

Small Molecule to Agonize CB1 Receptor for Inflammatory and Neuropathic Pain - Drug Profile

Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile

Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile

Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder - Drug Profile

Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile

Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile

Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile

Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile

Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile

Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile

Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile

Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile

Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile

Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile

Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile

Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile

Small Molecules to Modulate Mineralocorticoid Receptor for Anxiety Disorders and Depression - Drug Profile

Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile

Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile

Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile

SRX-246 - Drug Profile

SRX-251 - Drug Profile

STX - Drug Profile

Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile

TGFK-08AA - Drug Profile

TGSC-01AA(4) - Drug Profile

TNX-102 - Drug Profile

TRV-250 - Drug Profile

UCM-765 - Drug Profile

Vaccine for CNS Disorders - Drug Profile

VAD-1 - Drug Profile

VAD-2 - Drug Profile

VU-0431316 - Drug Profile

VU-0456810 - Drug Profile

ZL-006 - Drug Profile

Anxiety Disorders - Dormant Projects

Anxiety Disorders - Discontinued Products

Anxiety Disorders - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Anxiety Disorders, H2 2016

Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Investigation by Universities/Institutes, H2 2016

Anxiety Disorders - Pipeline by AbbVie Inc, H2 2016

Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016

Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2016

Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2016

Anxiety Disorders - Pipeline by Amorsa Therapeutics Inc., H2 2016

Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016

Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016

Anxiety Disorders - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016

Anxiety Disorders - Pipeline by Bionomics Limited, H2 2016

Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Anxiety Disorders - Pipeline by C4X Discovery Holdings PLC, H2 2016

Anxiety Disorders - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016

Anxiety Disorders - Pipeline by Corcept Therapeutics Incorporated, H2 2016

Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2016

Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2016

Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2016

Anxiety Disorders - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016

Anxiety Disorders - Pipeline by Gabather AB, H2 2016

Anxiety Disorders - Pipeline by GlaxoSmithKline Plc, H2 2016

Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H2 2016

Anxiety Disorders - Pipeline by Humanetics Corporation, H2 2016

Anxiety Disorders - Pipeline by IntelGenx Corp., H2 2016

Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H2 2016

Anxiety Disorders - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016

Anxiety Disorders - Pipeline by Lead Discovery Center GmbH, H2 2016

Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016

Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016

Anxiety Disorders - Pipeline by Neuralstem, Inc., H2 2016

Anxiety Disorders - Pipeline by Neurelis, Inc., H2 2016

Anxiety Disorders - Pipeline by NeuroNascent, Inc., H2 2016

Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016

Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016

Anxiety Disorders - Pipeline by Omeros Corporation, H2 2016

Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H2 2016

Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016

Anxiety Disorders - Pipeline by Pragma Therapeutics, H2 2016

Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H2 2016

Anxiety Disorders - Pipeline by Suda Ltd, H2 2016

Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016

Anxiety Disorders - Pipeline by Synchroneuron Inc., H2 2016

Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016

Anxiety Disorders - Pipeline by Toray Industries, Inc., H2 2016

Anxiety Disorders - Pipeline by Trevena, Inc., H2 2016

Anxiety Disorders - Pipeline by TRImaran Pharma, Inc., H2 2016

Anxiety Disorders - Pipeline by Turing Pharmaceuticals AG , H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Anxiety Disorders - Dormant Projects, H2 2016

Anxiety Disorders - Dormant Projects (Contd..1), H2 2016

Anxiety Disorders - Dormant Projects (Contd..2), H2 2016

Anxiety Disorders - Dormant Projects (Contd..3), H2 2016

Anxiety Disorders - Dormant Projects (Contd..4), H2 2016

Anxiety Disorders - Dormant Projects (Contd..5), H2 2016

Anxiety Disorders - Dormant Projects (Contd..6), H2 2016

Anxiety Disorders - Dormant Projects (Contd..7), H2 2016

Anxiety Disorders - Dormant Projects (Contd..8), H2 2016

Anxiety Disorders - Dormant Projects (Contd..9), H2 2016

Anxiety Disorders - Dormant Projects (Contd..10), H2 2016

Anxiety Disorders - Dormant Projects (Contd..11), H2 2016

Anxiety Disorders - Dormant Projects (Contd..12), H2 2016

Anxiety Disorders - Dormant Projects (Contd..13), H2 2016

Anxiety Disorders - Dormant Projects (Contd..14), H2 2016

Anxiety Disorders - Discontinued Products, H2 2016

Anxiety Disorders - Discontinued Products (Contd..1), H2 2016

Anxiety Disorders - Discontinued Products (Contd..2), H2 2016

Anxiety Disorders - Discontinued Products (Contd..3), H2 2016

Anxiety Disorders - Discontinued Products (Contd..4), H2 2016 260List of Figures

Number of Products under Development for Anxiety Disorders, H2 2016

Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Bionomics Limited
  • Gabather AB
  • IntelGenx Corp.
  • Omeros Corporation
  • Synchroneuron Inc.
  • MORE
Anxiety Disorders pipeline therapeutics constitutes close to 94 molecules. Out of which approximately 76 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Anxiety Disorders – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Anxiety Disorders Anxiety disorders are a group of mental illnesses that cause people to feel excessively frightened, distressed, or uneasy during situations in which most other people would not experience these same feelings. Symptoms include feelings of panic, fear, and uneasiness, problems sleeping, shortness of breath, heart palpitations, nausea, muscle tension and dizziness. Treatment includes antidepressant medications. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 8, 7, 2, 45, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 3 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc
Ache Laboratorios Farmaceuticos S/A
Adamed Sp. z o.o.
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Avineuro Pharmaceuticals, Inc.
Azevan Pharmaceuticals, Inc.
Biohaven Pharmaceutical Holding Company Limited
Bionomics Limited
Boehringer Ingelheim GmbH
C4X Discovery Holdings PLC
Catalyst Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated
Edgemont Pharmaceuticals, LLC
Eisai Co., Ltd.
Eli Lilly and Company
Fabre-Kramer Pharmaceuticals, Inc.
Gabather AB
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
Humanetics Corporation
IntelGenx Corp.
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Lead Discovery Center GmbH
Marinus Pharmaceuticals, Inc.
Merz Pharma GmbH & Co. KgaA
Neuralstem, Inc.
Neurelis, Inc.
NeuroNascent, Inc.
Newron Pharmaceuticals S.p.A.
Nippon Chemiphar Co., Ltd.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pherin Pharmaceuticals, Inc.
Pragma Therapeutics
Protagenic Therapeutics Inc.
Suda Ltd
Sumitomo Dainippon Pharma Co., Ltd.
Synchroneuron Inc.
Tonix Pharmaceuticals Holding Corp.
Toray Industries, Inc.
Trevena, Inc.
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll